Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Cyclophosphamide 1499Cisplatin 1436Paclitaxel 1342Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1135Bevacizumab 1071Fluorouracil 907Doxorubicin 805Dexamethasone 755Rituximab 745Capecitabine 736Oxaliplatin 710pembrolizumab 700Etoposide 679Irinotecan 641Filgrastim 624Nivolumab 588Cytarabine 587Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 437

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × apraclonidine × Clear all
NCT05045248 2021-09-16

Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

American University of Beirut Medical Center

Phase 2 Completed
10 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡